Metastatic or Locally Advanced Unresectable Solid TumorsPhase 1NCT05396833
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
A Phase 1 study testing Tuvusertib, Lartesertib and Avelumab in people with Metastatic or Locally Advanced Unresectable Solid Tumors, run by EMD Serono Research & Development Institute, Inc. at 22 sites in 5 countries.
Trial summary
This is an open-label, multicenter, clinical study conducted in multiple parts to establish the safety, tolerability, Pharmacokinetic/Pharmacodynamic (PK/PD) profile, maximum tolerated dose (MTD) combinations (if observed) and recommended dose for expansion (RDE) combination for tuvusertib in combination with… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Metastatic or Locally Advanced Unresectable Solid Tumors
- What is being tested?
- Tuvusertib, Lartesertib and Avelumab
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 22 sitesin 5 countries
- Study dates
- 7 Jun 2022to 14 Jul 2026
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Parts A1, A1.1, A1.2, A2, A3, and A2/3: Participants with metastatic or locally advanced unresectable solid tumors refractory to standard therapy or for which no standard therapy is judged appropriate by the Investigator, which may convey clinical benefit, or who cannot tolerate standard of care treatment
- Parts A1.1 and A1.2: Triple negative breast cancer, epithelial ovarian cancer, castrate resistant prostate cancer, urothelial cancer, endometrial cancer, and colorectal cancer independent of mutation status.
- Part A2: Participants with advanced prostate cancer whose tumor carries a genetic loss of function (LoF) mutation(s) in the gene ataxia telangiectasia mutated (ATM). No more than 3 prior lines of therapy for castrate resistant disease. Prior therapy must have included a taxane and a novel antiandrogen (example [e.g.] enzalutamide).
- Part A3: Participants with advanced endometrial cancer whose tumor carries a genetic LoF mutation(s) in the gene AT-rich interaction domain 1A (ARID1A). Prior therapy must have included a platinum agent. Prior therapy must also have included a checkpoint inhibitor if the participant has mismatch repair (MMR)-deficient endometrial cancer. Note for Parts A2/A3: Participants with ATM LoF mutated prostate cancer and ARID1A LoF mutated endometrial cancer should be prioritized to the respective expansion arms instead of being enrolled in Part A1.1. The presence of ATM and ARID1A LoF mutations will be determined according to historic data collected prior to prescreening, generated by an assay with appropriate regulatory status, in either tumor or liquid biopsy. The Sponsor will confirm that mutations certified by historic data fulfil this definition.
- Participants with eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, with estimated life expectancy of at least 3 months
- Adequate hematological, hepatic, and renal function as defined in the protocol
- Other protocol defined inclusion criteria could apply
Who cannot join
- Participants with any condition, including any uncontrolled disease state other than with metastatic or locally advanced unresectable solid tumors, that in the Investigator's opinion constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
- Participants with a known additional malignancy that is progressing and/or requires active treatment
- Participants with carcinomatous meningitis are excluded regardless of clinical stability
- Participants with serious gastrointestinal bleeding within 3 months, refractory nausea and vomiting, uncontrolled diarrhea, known malabsorption, significant small bowel resection or gastric bypass surgery, use of feeding tubes, other chronic gastrointestinal disease, and/or other situations that may preclude adequate absorption of oral medications
- Participants with organ transplantation, including allogeneic stem cell transplant
- Other protocol defined exclusion criteria could apply
Trial locations and contacts
22 sites in 5 countries.
22 sites in 5 countries
United States8 sites
Augusta University - formerly Georgia Regents University
Augusta, Georgia, 30912
Mary Crowley Cancer Research Centers
Dallas, Texas, 75230
University of Texas M. D. Anderson Cancer Center - Partner
Houston, Texas, 77030
The University of Kansas Medical Center Research Institute, Inc.
Kansas City, Kansas, 66205
University of Miami School of Medicine
Miami, Florida, 33136
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572
NEXT Oncology
San Antonio, Texas, 78229
Providence Medical Foundation
Santa Rosa, California, 95403
South Korea6 sites
Seoul National University Bundang Hospital
Seongnam-si, 13620
Severance Hospital, Yonsei University Health System - Division of Infectious Diseases
Seoul, 03722
Asan Medical Center
Seoul, 05505
Samsung Medical Center
Seoul, 06351
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, 06591
Korea University Guro Hospital
Seoul, 08308
Spain5 sites
Hospital QuironSalud Barcelona - Next Oncology
Barcelona, 08023
Hospital Clinic de Barcelona - Servicio de Oncologia
Barcelona
Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica
Madrid, 28050
Hospital Universitario Quironsalud Madrid - NEXT Oncology
Madrid, 28223
Hospital Universitario Fundacion Jimenez Diaz - START Madrid FJD - Oncology Phase I
Madrid
Australia2 sites
Royal North Shore Hospital
St Leonards
Calvary Mater Newcastle - PARENT
Waratah
About this study
Official title: An Open-label, Multicenter Phase Ib Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the ATR Inhibitor Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors in Patients With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 320)
This is an open-label, multicenter, clinical study conducted in multiple parts to establish the safety, tolerability, Pharmacokinetic/Pharmacodynamic (PK/PD) profile, maximum tolerated dose (MTD) combinations (if observed) and recommended dose for expansion (RDE) combination for tuvusertib in combination with lartesertib (in Part A1), food effect on the PK of lartesertib as monotherapy followed by treatment with tuvusertib in combination with lartesertib in participants with specific tumor types (in Part A1.1), relative bioavailability of a tuvusertib tablet formulation vs capsule formulation followed by treatment with tuvusertib (capsule) in combination with lartesertib in participants with specific tumor types (in Part A1.2), safety/tolerability and early signs of clinical activity of tuvusertib (capsule)and lartesertib in combination in participants with prostate cancer harboring loss of function (LoS) mutation in the gene ATM based on historic data collected prior to prescreening in circulating tumor (ct) DNA (liquid biopsies) or tumor biopsies (in Part A2), safety/tolerability and early signs of clinical activity of tuvusertib and lartesertib in combination in participants with endometrial cancer harboring LoS mutation(s) in the gene ARID1A based on historic data collected prior to prescreening in ctDNA (liquid biopsies) or tumor biopsies (in Part A3), the relative bioavailability of a tuvusertib tablet formulation (TF1, test) compared to a capsule formulation (reference) will also be investigated (in Part A2/A3), and identify a potential set of MTD combinations, and establish the RDE for the combination of tuvusertib and avelumab in participants with metastatic or locally advanced unresectable solid tumors (in Part B1).
- Being tested
- Tuvusertib, Lartesertib, Avelumab
- Keywords
- ATR inhibitor, ATM inhibitor, Immunotherapy, Tuvusertib (M1774), Lartesertib (M4076), Avelumab, Metastatic or Locally Advanced Unresectable Solid Tumors, DNA Damage Response Inhibitor, Immune Checkpoint Inhibitor
- Medical subject headings
- Neoplasm Metastasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TuvusertibDrug
Also called M1774
Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
LartesertibDrug
Also called M4076
Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.
AvelumabDrug
Avelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study.
| Study group | Role | What they receive |
|---|---|---|
| Part A1: Tuvusertib and Lartesertib | Experimental | Not described Receives: Drug: Tuvusertib; Drug: Lartesertib |
| Part A1.1: Tuvusertib and Lartesertib | Experimental | Assessment of the Effect of Food (Low-fat Meal) on the PK of M4076 Monotherapy Followed by Treatment with M1774 in Combination with M4076 Receives: Drug: Tuvusertib; Drug: Lartesertib |
| Part A1.2: Tuvusertib and Lartesertib | Experimental | Relative Bioavailability Assessment of Tuvusertib Tablet (TF1) vs Capsule Followed by Treatment with Tuvusertib in Combination with Lartesertib Receives: Drug: Tuvusertib; Drug: Lartesertib |
| Part A2: Tuvusertib and Lartesertib | Experimental | ATM in prostate cancer (Part A2) Receives: Drug: Tuvusertib; Drug: Lartesertib |
| Part A3: Tuvusertib and Lartesertib | Experimental | ARID1A in endometrial cancer Receives: Drug: Tuvusertib; Drug: Lartesertib |
| Part A2/A3: Tuvusertib and Lartesertib | Experimental | Tablet formulation (TF1, test) compared to a capsule formulation (reference) Receives: Drug: Tuvusertib; Drug: Lartesertib |
| Part B1: Tuvusertib and Avelumab | Experimental | Not described Receives: Drug: Tuvusertib; Drug: Avelumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Part A1: Number of Participants With Dose-Limiting Toxicities (DLTs) During the DLT Evaluation Period
Measured: Day 1 up to Day 28
Part A1: Number of Participants With Adverse Events (AEs) and Treatment-Related AEs
Measured: Baseline up to 18 months
Part B1: Number of Participants with Dose-Limiting Toxicities (DLTs) During the DLT Evaluation Period
Measured: Day 1 up to Day 28
Part B1: Number of Participants with AEs and Treatment-Related AEs
Measured: Baseline up to 18 months
Part A1: Change From Baseline in Pharmacodynamic (PD) Biomarker
The PD biomarker of histone variant will be measured by flow cytometry.
Measured: Pre-dose up to approximately 1 month
Part B1: Change From Baseline in PD Biomarker
The PD biomarker of histone variant will be measured by flow cytometry.
Measured: Pre-dose up to approximately 1 month
Part A1.1: PK Plasma Concentration of Lartesertib Under Fed and Fasted Conditions
Measured: Day -1 up to Period 1 Day 1
Part A2/A3: Objective Response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by Investigator
Measured: Up to 18 months after first dose administration
Part A2/A3: Number of Participants With AEs and Treatment-Related AEs
Measured: Baseline up to 18 months
Part A1.2: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference Treatment
Measured: Day -4 up to Period 1 Day 1
Part A1.2: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero to Last Quantifiable Concentration [Frel(AUC0-t)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference Treatment
Measured: Day -4 up to Period 1 Day 1
Part A1.2: Ratio Maximum Observed Plasma Concentration (Ratio[Cmax]) of Tuvusertib Test Treatment Compared to Tuvusertib Reference Treatment
Measured: Day -4 up to Period 1 Day 1
Part A2/A3: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference Treatment
Measured: Day -4 up to Period 1 Day 1
Part A2/A3: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero to Last Quantifiable Concentration [Frel(AUC0-t)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference Treatment
Measured: Day -4 up to Period 1 Day 1
Part A2/A3: Ratio Maximum Observed Plasma Concentration (Ratio[Cmax]) of Tuvusertib Test Treatment Compared to Tuvusertib Reference Treatment
Measured: Day -4 up to Period 1 Day 1
Secondary outcomes (12)
Part A1: Pharmacokinetic (PK) Plasma Concentration of Tuvusertib and Lartesertib
Measured: Pre-dose up to approximately 6 months
Parts A1.2 and B1: Pharmacokinetic (PK) Plasma Concentration of Tuvusertib
Measured: Pre-dose up to approximately 6 months
Part B1: Pharmacokinetic (PK) Serum Concentration of Avelumab
Measured: Pre-dose up to approximately 18 months
Part A1 and B1: Number of Participants with Clinically Significant Abnormalities in Digital Electrocardiogram (ECG) Measures
Measured: Baseline up to 18 months
Part A1 and B1: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumor (RECIST) v1.1
Measured: Up to 18 months after first dose administration
Part B1: Number of Participants with Any Positive Anti-Drug Antibody (ADA) of Avelumab
Measured: Baseline up to 18 months
Parts A1.1, A1.2 and A2/3: Number of Participants With AEs and Treatment-Related AEs
Measured: Baseline up to 18 months
Part A1.1: PK Plasma and Urine Concentration of Lartesertib Under Fed and Fasted Conditions
Measured: Day -1 up to Period 1 Day 1
Part A2/A3: Time to Reach Maximum Plasma Concentration (tmax) of Tuvusertib
Measured: Day -4 up to Period 1 Day 1
Part A2/A3: Duration of Response according to RECIST v1.1
Measured: Up to 18 months after first dose administration
Part A2/A3: Clinical benefit (either OR or stable disease for 6 months or more) according to RECIST v1.1.
Measured: Up to 18 months after first dose administration
Part A2/A3: Progression Free Survival according to RECIST v1.1 modified according to the Prostate Cancer Working Group 3 (PCWG-3), assessed by Investigator
Measured: Up to 18 months after first dose administration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 May 2022
- Study start7 Jun 2022
- Primary completion14 Jul 2026
- Study completion14 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metastatic or Locally Advanced Unresectable Solid TumorsStudies of the same condition, open and under way.
- More trials run by EMD Serono Research & Development Institute, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Merck KGaA, Darmstadt, Germany
- Responsible party
- Sponsor
- Investigators
- Medical Responsible, Study director, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05396833
- Sponsor's protocol ID
- MS201924_0020
- Other IDs
- 2022-500287-35-00
- Status last verified
- Sep 2026
- First submitted
- 24 May 2022
- Last updated
- 14 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Multicenter Phase Ib Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the ATR Inhibitor Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors in Patients With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 320)
- ClinicalTrials.gov ID
- NCT05396833
- Acronym / sponsor ID
- MS201924_0020
- Keywords
- ATR inhibitor, ATM inhibitor, Immunotherapy, Tuvusertib (M1774), Lartesertib (M4076), Avelumab, Metastatic or Locally Advanced Unresectable Solid Tumors, DNA Damage Response Inhibitor
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Merck KGaA, Darmstadt, Germany
- Study start
- 7 Jun 2022 (actual)
- Primary completion
- 14 Jul 2026 (actual)
- Study completion
- 14 Jul 2026 (actual)
- First posted
- 31 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an open-label, multicenter, clinical study conducted in multiple parts to establish the safety, tolerability, Pharmacokinetic/Pharmacodynamic (PK/PD) profile, maximum tolerated dose (MTD) combinations (if observed) and recommended dose for expansion (RDE) combination for tuvusertib in combination with lartesertib (in Part A1), food effect on the PK of lartesertib as monotherapy followed by treatment with tuvusertib in combination with lartesertib in participants with specific tumor types (in Part A1.1), relative bioavailability of a tuvusertib tablet formulation vs capsule formulation followed by treatment with tuvusertib (capsule) in combination with lartesertib in participants with specific tumor types (in Part A1.2), safety/tolerability and early signs of clinical activity of tuvusertib (capsule)and lartesertib in combination in participants with prostate cancer harboring loss of function (LoS) mutation in the gene ATM based on historic data collected prior to prescreening in circulating tumor (ct) DNA (liquid biopsies) or tumor biopsies (in Part A2), safety/tolerability and early signs of clinical activity of tuvusertib and lartesertib in combination in participants with endometrial cancer harboring LoS mutation(s) in the gene ARID1A based on historic data collected prior to prescreening in ctDNA (liquid biopsies) or tumor biopsies (in Part A3), the relative bioavailability of a tuvusertib tablet formulation (TF1, test) compared to a capsule formulation (reference) will also be investigated (in Part A2/A3), and identify a potential set of MTD combinations, and establish the RDE for the combination of tuvusertib and avelumab in participants with metastatic or locally advanced unresectable solid tumors (in Part B1).
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 7
| Arm | Type | Receives |
|---|---|---|
| Part A1: Tuvusertib and Lartesertib | Experimental | Drug: Tuvusertib, Drug: Lartesertib |
| Part A1.1: Tuvusertib and Lartesertib | Experimental | Drug: Tuvusertib, Drug: LartesertibAssessment of the Effect of Food (Low-fat Meal) on the PK of M4076 Monotherapy Followed by Treatment with M1774 in Combination with M4076 |
| Part A1.2: Tuvusertib and Lartesertib | Experimental | Drug: Tuvusertib, Drug: LartesertibRelative Bioavailability Assessment of Tuvusertib Tablet (TF1) vs Capsule Followed by Treatment with Tuvusertib in Combination with Lartesertib |
| Part A2: Tuvusertib and Lartesertib | Experimental | Drug: Tuvusertib, Drug: LartesertibATM in prostate cancer (Part A2) |
| Part A3: Tuvusertib and Lartesertib | Experimental | Drug: Tuvusertib, Drug: LartesertibARID1A in endometrial cancer |
| Part A2/A3: Tuvusertib and Lartesertib | Experimental | Drug: Tuvusertib, Drug: LartesertibTablet formulation (TF1, test) compared to a capsule formulation (reference) |
| Part B1: Tuvusertib and Avelumab | Experimental | Drug: Tuvusertib, Drug: Avelumab |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Parts A1, A1.1, A1.2, A2, A3, and A2/3: Participants with metastatic or locally advanced unresectable solid tumors refractory to standard therapy or for which no standard therapy is judged appropriate by the Investigator, which may convey clinical benefit, or who cannot tolerate standard of care treatment
- Parts A1.1 and A1.2: Triple negative breast cancer, epithelial ovarian cancer, castrate resistant prostate cancer, urothelial cancer, endometrial cancer, and colorectal cancer independent of mutation status.
- Part A2: Participants with advanced prostate cancer whose tumor carries a genetic loss of function (LoF) mutation(s) in the gene ataxia telangiectasia mutated (ATM). No more than 3 prior lines of therapy for castrate resistant disease. Prior therapy must have included a taxane and a novel antiandrogen (example [e.g.] enzalutamide).
- Part A3: Participants with advanced endometrial cancer whose tumor carries a genetic LoF mutation(s) in the gene AT-rich interaction domain 1A (ARID1A). Prior therapy must have included a platinum agent. Prior therapy must also have included a checkpoint inhibitor if the participant has mismatch repair (MMR)-deficient endometrial cancer. Note for Parts A2/A3: Participants with ATM LoF mutated prostate cancer and ARID1A LoF mutated endometrial cancer should be prioritized to the respective expansion arms instead of being enrolled in Part A1.1. The presence of ATM and ARID1A LoF mutations will be determined according to historic data collected prior to prescreening, generated by an assay with appropriate regulatory status, in either tumor or liquid biopsy. The Sponsor will confirm that mutations certified by historic data fulfil this definition.
- Participants with eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, with estimated life expectancy of at least 3 months
Key exclusion criteria (6 listed)
- Participants with any condition, including any uncontrolled disease state other than with metastatic or locally advanced unresectable solid tumors, that in the Investigator's opinion constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
- Participants with a known additional malignancy that is progressing and/or requires active treatment
- Participants with carcinomatous meningitis are excluded regardless of clinical stability
- Participants with serious gastrointestinal bleeding within 3 months, refractory nausea and vomiting, uncontrolled diarrhea, known malabsorption, significant small bowel resection or gastric bypass surgery, use of feeding tubes, other chronic gastrointestinal disease, and/or other situations that may preclude adequate absorption of oral medications
- Participants with organ transplantation, including allogeneic stem cell transplant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TuvusertibAlso: M1774Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study. | Drug | Part A1.1: Tuvusertib and Lartesertib, Part A1.2: Tuvusertib and Lartesertib, Part A1: Tuvusertib and Lartesertib, Part A2/A3: Tuvusertib and Lartesertib, Part A2: Tuvusertib and Lartesertib, Part A3: Tuvusertib and Lartesertib, Part B1: Tuvusertib and Avelumab |
| LartesertibAlso: M4076Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study. | Drug | Part A1.1: Tuvusertib and Lartesertib, Part A1.2: Tuvusertib and Lartesertib, Part A1: Tuvusertib and Lartesertib, Part A2/A3: Tuvusertib and Lartesertib, Part A2: Tuvusertib and Lartesertib, Part A3: Tuvusertib and Lartesertib |
| AvelumabAvelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study. | Drug | Part B1: Tuvusertib and Avelumab |
Primary outcome
Part A1: Number of Participants With Dose-Limiting Toxicities (DLTs) During the DLT Evaluation Period
Time frame: Day 1 up to Day 28
Part A1: Number of Participants With Adverse Events (AEs) and Treatment-Related AEs
Time frame: Baseline up to 18 months
Part B1: Number of Participants with Dose-Limiting Toxicities (DLTs) During the DLT Evaluation Period
Time frame: Day 1 up to Day 28
Part B1: Number of Participants with AEs and Treatment-Related AEs
Time frame: Baseline up to 18 months
Part A1: Change From Baseline in Pharmacodynamic (PD) Biomarker
Time frame: Pre-dose up to approximately 1 month
The PD biomarker of histone variant will be measured by flow cytometry.
Part B1: Change From Baseline in PD Biomarker
Time frame: Pre-dose up to approximately 1 month
The PD biomarker of histone variant will be measured by flow cytometry.
Part A1.1: PK Plasma Concentration of Lartesertib Under Fed and Fasted Conditions
Time frame: Day -1 up to Period 1 Day 1
Part A2/A3: Objective Response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by Investigator
Time frame: Up to 18 months after first dose administration
Part A2/A3: Number of Participants With AEs and Treatment-Related AEs
Time frame: Baseline up to 18 months
Part A1.2: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference Treatment
Time frame: Day -4 up to Period 1 Day 1
Part A1.2: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero to Last Quantifiable Concentration [Frel(AUC0-t)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference Treatment
Time frame: Day -4 up to Period 1 Day 1
Part A1.2: Ratio Maximum Observed Plasma Concentration (Ratio[Cmax]) of Tuvusertib Test Treatment Compared to Tuvusertib Reference Treatment
Time frame: Day -4 up to Period 1 Day 1
Part A2/A3: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference Treatment
Time frame: Day -4 up to Period 1 Day 1
Part A2/A3: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero to Last Quantifiable Concentration [Frel(AUC0-t)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference Treatment
Time frame: Day -4 up to Period 1 Day 1
Part A2/A3: Ratio Maximum Observed Plasma Concentration (Ratio[Cmax]) of Tuvusertib Test Treatment Compared to Tuvusertib Reference Treatment
Time frame: Day -4 up to Period 1 Day 1
12 secondary outcomes
Part A1: Pharmacokinetic (PK) Plasma Concentration of Tuvusertib and Lartesertib
Time frame: Pre-dose up to approximately 6 months
Parts A1.2 and B1: Pharmacokinetic (PK) Plasma Concentration of Tuvusertib
Time frame: Pre-dose up to approximately 6 months
Part B1: Pharmacokinetic (PK) Serum Concentration of Avelumab
Time frame: Pre-dose up to approximately 18 months
Part A1 and B1: Number of Participants with Clinically Significant Abnormalities in Digital Electrocardiogram (ECG) Measures
Time frame: Baseline up to 18 months
Part A1 and B1: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumor (RECIST) v1.1
Time frame: Up to 18 months after first dose administration
Part B1: Number of Participants with Any Positive Anti-Drug Antibody (ADA) of Avelumab
Time frame: Baseline up to 18 months
Parts A1.1, A1.2 and A2/3: Number of Participants With AEs and Treatment-Related AEs
Time frame: Baseline up to 18 months
Part A1.1: PK Plasma and Urine Concentration of Lartesertib Under Fed and Fasted Conditions
Time frame: Day -1 up to Period 1 Day 1
Part A2/A3: Time to Reach Maximum Plasma Concentration (tmax) of Tuvusertib
Time frame: Day -4 up to Period 1 Day 1
Part A2/A3: Duration of Response according to RECIST v1.1
Time frame: Up to 18 months after first dose administration
Part A2/A3: Clinical benefit (either OR or stable disease for 6 months or more) according to RECIST v1.1.
Time frame: Up to 18 months after first dose administration
Part A2/A3: Progression Free Survival according to RECIST v1.1 modified according to the Prostate Cancer Working Group 3 (PCWG-3), assessed by Investigator
Time frame: Up to 18 months after first dose administration
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2026.
- Trial Awareness and Transparency websiteLink provided by the sponsor.
- US Medical Information website, Medical ResourcesLink provided by the sponsor.
- Individual participant dataSharing planned: No. IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.
Related trials for Metastatic or Locally Advanced Unresectable Solid Tumors
Active, not recruitingPhase 3
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
RecruitingPhase 2
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
RecruitingPhase 1
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Breast Cancer, Ovarian Cancer
RecruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
Not yet recruitingPhase 1
A Study of IBI3043 Treatment in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors
Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Responsible study director
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
22 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Tuvusertib, Lartesertib and Avelumab in people with Metastatic or Locally Advanced Unresectable Solid Tumors, run by EMD Serono Research & Development Institute, Inc. at 22 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 22 sites in United States, South Korea, Spain, Australia, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Part A1: Number of Participants With Dose-Limiting Toxicities (DLTs) During the DLT Evaluation Period (time frame: Day 1 up to Day 28). The study lists 15 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2026.